Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners EPS Diluted (Quarterly): -0.677 for Dec. 31, 2023
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.677 |
| September 30, 2023 | -0.3963 |
| June 30, 2023 | -0.5452 |
| March 31, 2023 | -0.4859 |
| December 31, 2022 | -0.5612 |
| September 30, 2022 | -0.4245 |
| June 30, 2022 | -0.1451 |
| Date | Value |
|---|---|
| March 31, 2022 | 5.002 |
| December 31, 2021 | -0.6075 |
| September 30, 2021 | -0.4139 |
| June 30, 2021 | -0.6149 |
| March 31, 2021 | -0.6302 |
| December 31, 2020 | -0.8519 |
| September 30, 2020 | -0.6525 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.8519
Minimum
Dec 2020
5.002
Maximum
Mar 2022
-0.1432
Average
-0.5532
Median
EPS Diluted (Quarterly) Benchmarks
| AC Immune SA | -0.206 |
| CRISPR Therapeutics AG | -1.43 |
| Addex Therapeutics Ltd | -4.062 |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -0.22 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -22.32M |
| Revenue (Quarterly) | 1.164M |
| Total Expenses (Quarterly) | 19.95M |
| Enterprise Value | -98.31M |
| Profit Margin (Quarterly) | -1.92K% |
| Earnings Yield | -55.67% |
| Normalized Earnings Yield | -51.07 |